Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sudapyridine DDI and Food Effect Study
NCT06701136Phase 1Not yet recruiting
- Sponsor
- Shanghai Jiatan Pharmatech
- Start
- May 2025
- Primary completion
- Oct 2025
- Modality
- Small Molecules
01
Overview
Phase 1, randomised, open-label trial of sudapyridine in pulmonary tuberculosis (TB) (3 arms), sponsored by Shanghai Jiatan Pharmatech. Primary endpoints: Peak Plasma Concentration at Day 21, Time to Maximum Plasma Concentration at Day 21 and 1 more. Planned start May 2025; status: not yet recruiting.
02
Drugs
sudapyridine
03
Conditions
pulmonary tuberculosis (TB)
Beyond the preview
Go deeper on NCT06701136.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06701136.